How can you ensure a confident transition to human trials?
Posted in News
|A new whitepaper is now available from The Jackson Laboratory, entitled ‘Evidence-based selection of the starting dose in first-in-human clinical trials using humanised mouse models‘.
This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development toolbox with humanised mouse models.
Download the whitepaper to learn more about:
- The importance of selecting appropriate starting doses in clinical trials.
- Why humanised mice better predict human responses to therapeutics.
- How to integrate humanised mice into the drug development process to enhance understanding of drug behaviour, toxicity, and efficacy in humans.
